External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ISC 2025

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Feb 6 / Roche and Genentech
Factors Impacting Racial and Ethnic Disparities in the Use of Intravenous Thrombolytics in a Large Western US Healthcare System
This retrospective analysis of patients with ischemic stroke evaluated racial, ethnic and geographic differences in administration of intravenous thrombolytics. Patient characteristics and treatment outcomes were derived from a system-wide stroke registry comprising 40 hospitals in the Western US.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 6 / Roche and Genentech
Quantifying the Health Equity Impact of Tenecteplase for Acute Ischemic Stroke in the United States: a Distributional Cost-Effectiveness Analysis
This distributional cost-effective analysis (DCEA) evaluated how tenecteplase within 4.5 hours of AIS symptom onset impacts overall health and health disparities in ischemic stroke considering race and ethnicity and geography in the US.
03:00 AM
Duration 30mins Los Angeles, USA
Quantifying the Health Equity Impact of Tenecteplase for Acute Ischemic Stroke in the United States: a Distributional Cost-Effectiveness Analysis
Thomas Majda, Elizabeth Mearns, Shih-Wen Lin, Barbara Purdon, Stacey Kowal

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 30mins Los Angeles, USA
Factors Impacting Racial and Ethnic Disparities in the Use of Intravenous Thrombolytics in a Large Western US Healthcare System
Stuchiner T, Lowenkopf T, Marginean H, Purdon B, Carman L, Kowal S, Lin SW, Mearns E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar